AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
NeoGenomics Reports Q2 Revenue of $181.3mln, Down from Estimates, Net Loss of $45.1mln.
ByAinvest
Sunday, Aug 17, 2025 11:11 am ET1min read
• Pomerantz LLP investigating NeoGenomics securities fraud claims • Investors advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980 • NeoGenomics reports Q2 2025 revenue of $181.3 million, below consensus estimates • Net loss of $45.1 million and reduced 2025 revenue forecast to $720-$726 million • Adjusted EBITDA projection lowered to $41-$45 million
New York, Aug. 2, 2025 — NeoGenomics (NASDAQ: NEO), a leading oncology diagnostics company, is facing a class action lawsuit alleging securities fraud. The lawsuit, filed by Pomerantz LLP, claims that the company and certain of its officers and/or directors engaged in unlawful business practices. Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980 to inquire about their rights [1].NeoGenomics reported its Q2 2025 earnings on July 29, 2025, revealing a 10.2% year-on-year increase in revenue to $181.3 million, which fell short of analysts' expectations of $182.9 million. The company's full-year revenue guidance was reduced to $723 million at the midpoint, down 2.9% from previous estimates. The company also reported a net loss of $45.1 million and an adjusted EBITDA projection of $41-$45 million, down from prior estimates [2].
The company attributed its underperformance to persistent pharma sector headwinds, a delayed launch of its PanTracer liquid biopsy product, and ongoing product mix challenges. Despite these headwinds, NeoGenomics highlighted solid growth in its core clinical business and continued share gains in high-value testing segments. The company expects the second half of the year to be shaped by the commercial rollout of new products, continued clinical market share gains, and a cautious outlook for its pharma services segment [2].
Investors should closely monitor the outcome of the class action lawsuit and the company's ability to execute on its strategic initiatives. The company's stock price fell to $5.84 after the earnings report, down from $6.48 before the announcement [2].
References:
[1] https://www.morningstar.com/news/globe-newswire/9510056/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-novo-nordisk-as-of-class-action-lawsuit-and-upcoming-deadlines-nvo
[2] https://finance.yahoo.com/news/neo-q2-deep-dive-guidance-045656424.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet